Alnylam’s long history, and promising future, of innovation

It’s been more than two years since Alnylam Pharmaceuticals Inc. earned U.S. approval for the world’s first drug based on a Nobel Prize-winning technology that can effectively silence any gene in the genome. But over the past year, it’s applied the same spirit of innovation to show how that science can form the basis of a large, sustainable company.